Editor: Acharya Balkrishna

Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices

eBook: US $59 Special Offer (PDF + Printed Copy): US $111
Printed Copy: US $82
Library License: US $236
ISBN: 978-981-5051-19-3 (Print)
ISBN: 978-981-5051-18-6 (Online)
Year of Publication: 2022
DOI: 10.2174/97898150511861220101

Introduction

This book details all the intricacies and essential knowledge involved in the research and development of the Coronil Kit – a combination of 3 ayurvedic medications for the common cold. It informs the reader about the huge potential of herbal drugs in fighting against any type of disease through evidence-based data from clinical trials and experiments. The book elaborates how current scientific techniques can be applied to understand the healing capacities of plants at their molecular level and thus utilize their different combinations to treat diseases by targeting harmful micro-organisms and simultaneously boosting the immune system. It covers methods of virtual screening and computational validation of identified phytochemicals as potential antiviral agents against the SARS-CoV-2 virus.

70 colored figures.

Key features:

- Covers the molecular etiology of COVID-19 virus

- Covers guidance on drug formulation, hazard assessment, and clinical trials based on approved methods by regulatory organizations

- Covers pharmacological, toxicological, and technically verified chemical composition of medicinal plants

- Includes information about in vivo experiments and analysis of Humanoid Zebrafish trials

- Includes methods of identifying antiviral agents against the SARS-CoV-2 virus

- Includes chemical, analytical and technical studies of Coronil

- Includes 70 images 7 chapters

- Includes a bibliography and appendix

The book is primarily intended as a primary resource for medical research scholars and researchers in pharmaceutical companies and as a secondary resource for B.A.M.S. students, medical postgraduate students, and Ayurveda enthusiasts.

Audience: Medical research scholars and researchers in pharmaceutical companies, B.A.M.S. students, medical postgraduate students, and Ayurveda enthusiasts.

Foreword

The COVID-19 pandemic has emerged as a global health emergency of international concern since its first identification, resulting in millions of deaths and economic disruption. The healthcare systems across the globe are at the hilt and being tested for effective management against COVID-19. Employing our ancient traditional system and integrative approach, our nation has dealt with this bolstering virus competently, which is evident from the significantly low mortality rates in India. Param Pujya Acharya Ji, with his sheer dedication, astute guidance, pragmatic approach, and deep knowledge of the ancient Indian traditional system of medicine, has written a new success story by developing an effective medicine against COVID-19.

Patanjali Research Institute, Haridwar, Uttarakhand, is a lineage representative of ancient Indian Vedic and sage traditions. A team of dedicated scientists at Patanjali Research Institute has worked relentlessly to develop Ayurvedic formulations into effective medicine by screening close to 1500 phytochemicals from more than 200 medicinal plants. This was a path-finding journey with experiences shared in this book titled “Ayurveda against COVID-19”. We hope that this body of work will serve as a capstone of guidance to develop a new series of Ayurvedic formulations into medicines that would be acceptable to the modern medical and scientific fraternity worldwide.

By sharing our research through this book, we wish to reach a greater and wider readership and, in the process, hope to materialize our humble efforts towards ensuring the well-being of humankind worldwide.

May this excellence of scientific practice in Ayurveda find its due destination!


Swami Ramdev

President and Co-founder
Patanjali Yogpeeth
Haridwar, Uttarakhand
India

RELATED BOOKS

.New Findings from Natural Substances.
.Indopathy for Neuroprotection: Recent Advances.
.Pharmaceuticals for Targeting Coronaviruses.